Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above Consensus

Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results

August 2, 2018 8:00 AM EDT

-- EXPAREL® net product sales of $80.4 million up 15% over prior year second quarter ---- Full-year EXPAREL net product sales guidance increased to $320 to $325 million ---- Conference Call Today at 8:30 a.m. ET --

PARSIPPANY, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the second quarter ended June 30, 2018.

The first half of 2018 was marked by tremendous progress as our EXPAREL growth strategy is taking hold and driving robust topline results, said Dave Stack, chairman and chief executive... More